Skip to search formSkip to main contentSkip to account menu

SLC5A2 gene

Known as: Solute Carrier Family 5 (Sodium/Glucose Cotransporter), Member 2 Gene, SGLT2, SODIUM-GLUCOSE COTRANSPORTER, KIDNEY LOW AFFINITY 
This gene is involved in the transport of both glucose and sodium.
National Institutes of Health

Related topics

Related topics

11 relations
Carbohydrate MetabolismHomo sapiensIonophore activityLigand Binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Glucagon Levels During Short-Term SGLT2 Inhibition Are Largely Regulated by Glucose Changes in Patients With Type 2 Diabetes
Context The mechanism mediating sodium glucose cotransporter-2 (SGLT2) inhibitor-associated increase in glucagon levels is… 
2018
2018
Cardiovascular benefits of SGLT2 inhibition in diabetes and chronic kidney diseases
In addition to being a leading cause of end-stage renal disease, diabetes mellitus is also associated with an elevated risk of… 
2018
2018
SGLT2 inhibitor-induced euglycaemic diabetic ketoacidosis may be due to abrupt, severe and transient impaired glucose sensing in susceptible individuals with a hitherto unrecognised beta cell SGLT…
2016
2016
Antihypertensive effects of SGLT2 inhibitors in type 2 diabetes.
2016
2016
Possible Increase in Serum FABP4 Level Despite Adiposity Reduction by Canagliflozin, an SGLT2 Inhibitor
Background Fatty acid-binding protein 4 (FABP4/A-FABP/aP2) is secreted from adipocytes in association with catecholamine-induced… 
2015
2015
Evaluating Drug Cost per Response with SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus.
BACKGROUND The sodium-glucose cotransporter 2 (SGLT2) inhibitors, which include canagliflozin, dapagliflozin, and empagliflozin… 
Review
2013
Review
2013
Canagliflozin, a Novel SGLT2 Inhibitor for Treatment of Type 2 Diabetes
Objective: To evaluate the available clinical data on canagliflozin and provide formulary considerations as to its place in the… 
2012
2012
SGLT2 inhibitors race to enter type-2 diabetes market
crowded class (Table 1). Candidate SGLT2 inhibitors that have progressed through latestage trials have demonstrated either… 
Review
2011
Review
2011
A paradigm shift in diabetes therapy--dapagliflozin and other SGLT2 inhibitors.
Blocking sodium-glucose cotransporters (SGLTs) to decrease the reabsorption of glucose--and thus increase renal glucose excretion… 
2005
2005
A 96-well automated method to study inhibitors of human sodium-dependent D-glucose transport
The sodium-dependent D-glucose transporter (SGLT) family is involved in glucose uptake via intestinal absorption (SGLT1) or renal… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)